Vsg-based vaccination and antibody generation platform for the treatment of diseases

Patent metadata

Field	Value
Publication number	US-12285474-B2
Application number	US-201917288208-A
Country	US
Kind code	B2
Filing date	Oct 24, 2019
Priority date	Oct 24, 2018
Publication date	Apr 29, 2025
Grant date	Apr 29, 2025

Abstract

The invention is based on a platform for vaccination and/or antibody generation. The invention is based on the display of small molecular immunogenic compounds on the coat of variant surface glycoproteins (VSG) on trypanosomes which results in a highly effective immune response when used as a vaccine or in immunization for antibody production. The herein disclosed antigenic particles are applicable for producing antibodies or can be directly used as vaccines for the treatment of various medical conditions. Most preferably the invention relates to the VSG based vaccines specific for dependency causing substances for the treatment of addiction or avoidance of adverse events during drug abuse. Other applications include methods and uses involving the disclosed compounds and compositions for a treatment or prevention of cancer, infectious disease, contagious neurodegenerative diseases, non-communicable disorders (e.g. certain neurodegenerative diseases, allergies) and any condition or industrial use for which an immune response from vaccination or antibody use would be desirable.

First claim

The invention claimed is:

1. An antigenic particle coated with an engineered variant surface glycoprotein (eVSG), wherein the eVSG comprises a VSG linked to an immunogenic compound, wherein the immunogenic compound is a small molecular drug, and which is covalently linked via a linker to the N-terminus of the VSG, wherein the VSG is VSG3 derived from the genome of T. brucei.

2. The antigenic particle according to claim 1 , wherein the eVSG has the following covalent structure from N- to C-terminus: immunogenic compound, a sortagging donor sequence, a sortagging acceptor sequence, a linker, and the VSG protein sequence.

3. The antigenic particle according to claim 1 , wherein the immunogenic compound is selected from (i) delta- 9 -tetrahydrocannabinol (THC) or synthetic cannabinoids or (ii) methamphetamine and derivatives thereof; or (iii) a synthetic cathinone; or (iv) an opioid; or (v) steroids, or is nicotine.

4. The antigenic particle according to claim 1 , wherein the particle is a biological cell, a vesicle, a nanoparticle or a bead.

5. The antigenic particle according to claim 4 , wherein the biological cell is a microorganism.

6. The antigenic particle according to claim 5 , wherein the biological cell is an inactivated biological cell.

7. An immunogenic engineered VSG (ieVSG) protein, comprising in N- to C-terminal direction:
(a) An immunogenic compound,
(b) A sortagging donor sequence,
(c) A sortagging acceptor sequence,
(d) A linker sequence,
(e) A full length, or essentially full length, VSG protein, wherein the VSG is VSG3 derived from the genome of T. brucei.

8. A system or kit, comprising as components (i) a pre-ieVSG protein and (ii) a compound comprising a sortagging donor sequence, wherein the pre-ieVSG protein comprises in N-to C-terminal direction:
(a′) Optionally a signal peptide,
(b′) A sortagging acceptor sequence,
(c′) A linker sequence,
(d′) A full length, or essentially full length, VSG protein, wherein the VSG is VSG3 derived from the genome of T. brucei.

9. The system or kit according to claim 8 , further comprising, a sortase enzyme, or means for the generation of a sortase enzyme.

10. The system or kit according to claim 8 , wherein the pre-ieVSG protein is provided as a nucleic acid sequence for the expression of a pre-ieVSG protein.

11. The system or kit according to claim 8 , further comprising means for covalently attaching the sortagging donor sequence to a compound used as immunogen.

Assignees

• Deutsches Krebsforschungszentrum Stiftung Des Oeffentlichen Rechts

Inventors

• Papavasiliou Fotini Nina
• Hashemi Hamidreza
• Triller Gianna
• Stebbins Erec
• Miller Aubry
• Baumann Andreas

Classifications

• A61K2039/6031

  Proteins · CPC title

• A61K2039/545

  characterised by the dose, timing or administration schedule · CPC title

• A61K2039/523

  expressing foreign proteins · CPC title

• A61K2039/521

  inactivated (killed) · CPC title

• A61K39/385 Primary

  Haptens or antigens, bound to carriers · CPC title